Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > February 2014 - Volume 21 - Issue 2 > Women’s Health Initiative clinical trials: interaction of ca...
Menopause:
doi: 10.1097/GME.0b013e3182963901
Original Articles

Women’s Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy

Robbins, John A. MD, MHS1; Aragaki, Aaron MS2; Crandall, Carolyn J. MD, MS3; Manson, JoAnn E. MD, DrPH4; Carbone, Laura MD5,6; Jackson, Rebecca MD7; Lewis, Cora Elizabeth CE, MD, MSPH8; Johnson, Karen C. MD, MPH9; Sarto, Gloria MD, PhD10; Stefanick, Marcia L. PhD11; Wactawski-Wende, Jean PhD12

Editorial
Collapse Box

Abstract

Objective

This study aims to test the added value of calcium and vitamin D (CaD) in fracture prevention among women taking postmenopausal hormone therapy (HT).

Methods

This is a prospective, partial-factorial, randomized, controlled, double-blind trial among Women’s Health Initiative postmenopausal participants aged 50 to 79 years at 40 centers in the United States with a mean follow-up of 7.2 years. A total of 27,347 women were randomized to HT (0.625 mg of conjugated estrogens alone, or 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily), and 36,282 women were randomized to 1,000 mg of elemental calcium (carbonate) plus 400 IU of vitamin D3 daily, each compared with placebo. A total of 16,089 women participated in both arms. The predefined outcomes were adjudicated hip fractures and measured bone mineral density.

Results

Interaction between HT and CaD on hip fracture (P interaction = 0.01) was shown. The effect of CaD was stronger among women assigned to HT (hazard ratio [HR], 0.59; 95% CI, 0.38-0.93) than among women assigned to placebo (HR, 1.20; 95% CI, 0.85-1.69). The effect of HT on hip fracture was stronger among women assigned to active CaD (HR, 0.43; 95% CI, 0.28-0.66) than among women assigned to placebo (HR, 0.87; 95% CI, 0.60-1.26). CaD supplementation enhanced the antifracture effect of HT at all levels of personal calcium intake. There was no interaction between HT and CaD on change in hip or spine bone mineral density.

Conclusions

Postmenopausal women at normal risk for hip fracture who are on CaD supplementation experience significantly reduced incident hip fractures beyond HT alone at all levels of personal baseline total calcium intake.

© 2013 by The North American Menopause Society

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.